151 related articles for article (PubMed ID: 33875416)
1. CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: a retrospective cohort study using electronic health records.
Funston G; Mounce LT; Price S; Rous B; Crosbie EJ; Hamilton W; Walter FM
Br J Gen Pract; 2021 Jun; 71(707):e465-e472. PubMed ID: 33875416
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study.
Funston G; Hamilton W; Abel G; Crosbie EJ; Rous B; Walter FM
PLoS Med; 2020 Oct; 17(10):e1003295. PubMed ID: 33112854
[TBL] [Abstract][Full Text] [Related]
3. Outcome of elevated CA125 values from primary care following implementation of ovarian cancer guidelines.
Crawford SM; Evans C
Fam Pract; 2018 Mar; 35(2):199-202. PubMed ID: 29029123
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less.
Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T; Oi H
Gynecol Obstet Invest; 2008; 65(2):133-8. PubMed ID: 17957102
[TBL] [Abstract][Full Text] [Related]
5. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
6. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
7. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
8. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
[TBL] [Abstract][Full Text] [Related]
10. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.
Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W
J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620
[TBL] [Abstract][Full Text] [Related]
11. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
13. Could Ovarian Cancer Prediction Models Improve the Triage of Symptomatic Women in Primary Care? A Modelling Study Using Routinely Collected Data.
Funston G; Abel G; Crosbie EJ; Hamilton W; Walter FM
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207611
[TBL] [Abstract][Full Text] [Related]
14. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
15. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
[No Abstract] [Full Text] [Related]
16. Serum CA125 level before the development of ovarian cancer.
Kobayashi H; Ooi H; Yamada Y; Sakata M; Kawaguchi R; Kanayama S; Sumimoto K; Terao T
Int J Gynaecol Obstet; 2007 Nov; 99(2):95-9. PubMed ID: 17643440
[TBL] [Abstract][Full Text] [Related]
17. Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.
Mansha M; Gill A; Thomson PC
Mol Biol Rep; 2019 Jun; 46(3):3325-3332. PubMed ID: 31006098
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.
Menon U; Talaat A; Jeyarajah AR; Rosenthal AN; MacDonald ND; Skates SJ; Sibley K; Oram DH; Jacobs IJ
Br J Cancer; 1999 Jul; 80(10):1644-7. PubMed ID: 10408412
[TBL] [Abstract][Full Text] [Related]
19. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
[TBL] [Abstract][Full Text] [Related]
20. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S;
Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
